Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Competitor Shortages Allow Amphastar To Deliver ‘Strongest Quarter Yet’

Pending Launches Expected To Drive Future Growth

Executive Summary

After shortages at competitor companies opened up gaps in the market Amphastar was able to step in to fill the void, leading to its most successful quarter yet with net revenues of $135m.

You may also be interested in...



Amphastar Beats The Street For Third Consecutive Quarter

Amphastar has continued to surpass expectations for the third quarter in a row, as staggering growth of its glucagon injection propelled it to an 18% year-on-year revenue increase.

The Generics Bulletin Top 50, Part Three: Final Firms Enjoy Mixed Fortunes

In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel